Hypertension in detail
Reading File
Finding Sources
Searching PubMed
"hypertension" AND "management"
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Loading Image
Finding Sources
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me compile the full detailed response.
Hypertension - A Detailed Overview
1. Definition and Classification
Hypertension is a persistent elevation of blood pressure beyond accepted normal values, conferring increased risk of cardiovascular, cerebrovascular, and renal injury. Classification differs by guideline system:
ACC/AHA 2017 Classification (used in Harrison's 22e, Fuster's Heart 15e):
| BP Category | Systolic (mmHg) | Diastolic (mmHg) | |
|---|---|---|---|
| Normal | <120 | and | <80 |
| Elevated | 120-129 | and | <80 |
| Stage 1 Hypertension | 130-139 | or | 80-89 |
| Stage 2 Hypertension | ≥140 | or | ≥90 |
JNC / older guidelines (still used in some countries): Stage 1 = 140-159/90-99 mmHg; Stage 2 = ≥160/≥100 mmHg.
Correct classification requires averaging two or more readings at two or more separate visits. When systolic and diastolic fall in different categories, the higher category is used. In children <13 years, hypertension is defined by age-, sex-, and height-specific normative data (≥95th percentile or ≥130/80 mmHg). - Harrison's Principles of Internal Medicine 22E, Table 288-1
2. Epidemiology
- Affects an estimated 1.28 billion adults globally
- Accounts for ~50% of all strokes and ~45% of ischemic heart disease deaths worldwide
- Prevalence rises sharply with age: <10% at age 20-30 to >70% in those over 70
- More common and more severe in Black patients, who are at disproportionately higher risk of end-organ damage at any given BP level
- Overweight and obesity account for 65-75% of the risk for primary hypertension - Fuster and Hurst's The Heart, 15th Edition
3. Classification by Etiology
3a. Primary (Essential) Hypertension (~90-95% of cases)
Primary hypertension is defined as elevated BP without an identifiable single secondary cause. It is heterogeneous in mechanism. Key contributing factors include:
Overweight and Obesity (the dominant cause):
- Obesity drives hypertension through two primary mechanisms: sympathetic nervous system (SNS) activation and RAAS activation
- Leptin, secreted by adipocytes, stimulates POMC neurons in the arcuate nucleus → activates melanocortin 4 receptors (MC4R) → increases renal sympathetic nerve activity and raises BP
- Obese subjects show increases in plasma renin activity, angiotensinogen, ACE activity, angiotensin II, and aldosterone - despite volume expansion (which would normally suppress the RAAS)
- Visceral adiposity generates pro-inflammatory cytokines (IL-6, TNF-alpha, CRP), contributing to endothelial dysfunction and atherosclerosis
Other identifiable contributors:
-
Sedentary lifestyle
-
Excess sodium chloride intake
-
Excess alcohol consumption
-
Low potassium intake
-
Genetic predisposition (multiple loci involved; see monogenic causes below)
-
Fuster and Hurst's The Heart, 15th Edition, p. 243-246
3b. Secondary Hypertension (~5-10% of cases)
Consider secondary causes when: severe/resistant hypertension, abrupt BP rise from a previously stable value, onset before puberty, nonobese patient <30 years, or hypertension with specific clinical clues.
The causes of secondary hypertension fall into four categories:
A. Vascular Causes:
- Renal artery stenosis - responsible for up to 20% of resistant hypertension. Fibromuscular dysplasia (FMD) is the most common cause in children and young adults (classic "string of beads" on angiography). Atherosclerosis is the most common cause in older adults. Clues: abdominal bruit (especially diastolic), acute renal function decline after starting ACEi/ARB. Gold standard diagnosis: conventional renal angiography; initial screening: duplex ultrasonography
- Coarctation of the aorta - discordant BP between upper and lower extremities; rib notching on chest X-ray
- Vasculitis (e.g., polyarteritis nodosa, Takayasu arteritis)
- Frameworks for Internal Medicine
B. Endocrinologic Causes:
- Primary aldosteronism (Conn syndrome) - aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). Features: hypertension + hypokalemia + metabolic alkalosis + suppressed renin. Diagnosis: aldosterone-to-renin ratio (elevated); confirm with adrenal CT ± adrenal vein sampling
- Pheochromocytoma - catecholamine-secreting tumor (adrenal or extra-adrenal chromaffin). Episodic headache, palpitations, sweating. Diagnosis: plasma free metanephrines or 24-hr urinary metanephrines
- Cushing syndrome - glucocorticoid excess activates mineralocorticoid receptors (cortisol bypasses normal 11β-HSD2 protection)
- Acromegaly - GH excess
- Renin-producing tumors (rare)
- Fuster and Hurst's The Heart, 15th Edition, Table 5-4
C. Renal Parenchymal Causes:
- Acute/chronic glomerulonephritis
- Polycystic kidney disease
- Diabetic nephropathy
- Hydronephrosis
D. Toxic/Drug-Induced:
- NSAIDs (inhibit prostaglandin-mediated vasodilation, cause sodium retention)
- Oral contraceptives/glucocorticoids/mineralocorticoids
- Sympathomimetics
- Cyclosporine
- Excess alcohol
- Cocaine/amphetamines
- Licorice (inhibits 11β-HSD2, allowing cortisol to activate MR)
- Tyramine-containing foods + MAOIs
E. Other:
- Pregnancy-induced hypertension / preeclampsia
- Obstructive sleep apnea (most common endocrine cause of secondary HTN in some classifications)
- Increased intracranial pressure
- Fuster and Hurst's The Heart, 15th Edition; Frameworks for Internal Medicine
4. Monogenic (Genetic) Causes of Hypertension
| Genetic Disorder | Age of Onset | Inheritance | Aldosterone | K+ | Treatment |
|---|---|---|---|---|---|
| Apparent mineralocorticoid excess (AME) | Childhood | Autosomal recessive | Low | Low/normal | Dexamethasone, MR antagonist, amiloride |
| Liddle syndrome | 3rd decade | Autosomal dominant | Low | Low/normal | Amiloride, triamterene |
| Gordon syndrome | 2nd-3rd decade | Autosomal dominant | Low | High | Thiazide, low-Na diet |
| FH-I (glucocorticoid-remediable aldosteronism) | 2nd-3rd decade | Autosomal dominant | High | Low | Glucocorticoids, MR antagonist |
| FH-II | Middle age | Autosomal dominant | High | Low/normal | MR antagonist |
| CAH (11-hydroxylase or 17-hydroxylase deficiency) | Childhood | Autosomal recessive | Low | Low/normal | Glucocorticoids |
- Fuster and Hurst's The Heart, 15th Edition, Table 5-5
5. Pathophysiology
Renal-Pressure Natriuresis Mechanism
The kidney plays a central long-term role in BP regulation. Any factor that impairs renal pressure natriuresis (the ability of the kidney to excrete sodium in response to elevated pressure) will result in sustained hypertension.
RAAS (Renin-Angiotensin-Aldosterone System)
- Renin (from juxtaglomerular cells) cleaves angiotensinogen → Angiotensin I → (ACE) → Angiotensin II
- Ang II: potent vasoconstrictor; stimulates aldosterone secretion; promotes renal sodium/water retention; stimulates SNS
- Aldosterone acts on principal cells of collecting duct → increases Na+ reabsorption (ENaC) and K+ secretion
Sympathetic Nervous System
- Chronic SNS activation raises BP via: increased heart rate, increased cardiac output, peripheral vasoconstriction, and direct renal tubular sodium retention
- Obesity-induced SNS activation via the leptin-POMC-MC4R pathway is a central mechanism
Endothelial Dysfunction
- Chronic hypertension causes endothelial injury → reduced nitric oxide bioavailability → impaired vasodilation → vascular remodeling (hypertrophy of media) → further BP elevation
Vascular Stiffness
- Aging and chronic hypertension lead to arterial stiffening → increased pulse wave velocity → isolated systolic hypertension (common in the elderly)
6. Target Organ Damage
Uncontrolled hypertension damages multiple organs:
| Organ | Manifestation |
|---|---|
| Heart | LV hypertrophy, heart failure (HFpEF and HFrEF), coronary artery disease, MI |
| Brain | Ischemic stroke, intracerebral hemorrhage, lacunar infarcts, vascular dementia |
| Kidney | Hypertensive nephrosclerosis, CKD, proteinuria, renal failure |
| Eyes | Hypertensive retinopathy (AV nicking, copper/silver wiring, flame hemorrhages, papilledema in severe cases) |
| Vessels | Aortic dissection, peripheral arterial disease, aneurysm formation |
Hypertension carries a 2.5-fold (men) to 3.9-fold (women) age-adjusted risk for peripheral arterial disease. - Textbook of Family Medicine 9e
7. Diagnosis and Evaluation
BP Measurement
- Use a clinically validated oscillometric device
- Average 2+ readings at 2+ visits
- Commonly SBP is overestimated by ~7 mmHg in clinical practice, resulting in 15-20% overestimation of hypertension prevalence
- Consider ambulatory BP monitoring (ABPM) to detect white coat hypertension (~15-30% of office diagnoses) or masked hypertension
Initial Workup
All patients:
- Basic metabolic panel (serum K+, creatinine, eGFR)
- Urinalysis with microscopy
- Fasting lipid panel, glucose, HbA1c
- 12-lead ECG (LVH?)
- Thyroid function
When secondary hypertension is suspected:
- Aldosterone-to-renin ratio (primary aldosteronism)
- Plasma free metanephrines / 24-hr urinary metanephrines (pheochromocytoma)
- Renal duplex ultrasound (renovascular)
- Overnight 1 mg DST or 24-hr urinary free cortisol (Cushing's)
- Renal ultrasound for size/symmetry
8. Treatment
8a. Lifestyle Interventions (First-line for all patients)
| Intervention | Expected SBP Reduction |
|---|---|
| DASH diet | 8-14 mmHg |
| Sodium restriction (<1.5 g/day) | 5-6 mmHg |
| Weight loss (per 10 kg) | 5-20 mmHg |
| Regular aerobic exercise (30 min, 5x/week) | 4-9 mmHg |
| Limit alcohol (≤2 drinks/day men, ≤1 women) | 2-4 mmHg |
| Stop smoking | Reduces overall CV risk significantly |
8b. Pharmacological Therapy
Who needs drugs?
- All adults with Stage 2 hypertension
- Stage 1 hypertension + prior CVD or 10-year ASCVD risk ≥10%
First-line drug classes (all proven to reduce CVD outcomes vs placebo):
- Thiazide/thiazide-like diuretics - especially chlorthalidone (longer-acting, superior to HCTZ for CV outcomes)
- Dihydropyridine calcium channel blockers (CCBs) - amlodipine is prototype
- ACE inhibitors (ACEi) - captopril, lisinopril, ramipril
- Angiotensin receptor blockers (ARBs) - losartan, valsartan
Combination therapy:
- Most patients with BP >150/90 mmHg need 2 drugs at initiation
- Effective 2-drug combinations: Diuretic + CCB, Diuretic + ACEi/ARB, CCB + ACEi/ARB
- Effective 3-drug combination: Diuretic + CCB + ACEi/ARB
- Avoid: ACEi + ARB combination (harmful - dual RAAS blockade)
Resistant hypertension (BP uncontrolled on ≥3 full-dose agents including a diuretic):
- Add spironolactone (MR antagonist - particularly effective in obese patients with resistant HTN)
- Consider: alpha-blocker, beta-blocker
- Longer-acting diuretic substitution (chlorthalidone instead of HCTZ)
Compelling indications for specific drug classes:
| Condition | Preferred Agent(s) |
|---|---|
| Heart failure (HFrEF) | ACEi/ARB, beta-blocker, aldosterone antagonist, diuretic |
| Post-MI | Beta-blocker, ACEi/ARB |
| CKD with proteinuria | ACEi or ARB |
| Diabetes | ACEi or ARB (renoprotective) |
| Renovascular HTN | ACEi/ARB (with caution - monitor renal function) |
| Primary aldosteronism | MR antagonist (spironolactone) |
| PAD | ACEi preferred; beta-blockers are safe and do NOT worsen IC |
| Pregnancy | Labetalol, methyldopa, nifedipine (NOT ACEi/ARBs - teratogenic) |
| Black patients | CCB or thiazide diuretic preferred (ACEi less effective as monotherapy) |
8c. BP Targets
| Population | Target |
|---|---|
| General adults | <130/80 mmHg (ACC/AHA) |
| Community-dwelling adults ≥65 years | SBP <130 mmHg |
| Older adults with high comorbidity burden | Individualized based on clinical judgment |
- Fuster and Hurst's The Heart, 15th Edition, p. 250
9. Hypertensive Crisis
Hypertensive Emergency
- Marked BP elevation (typically >180/120 mmHg) with acute target organ damage
- Manifestations: hypertensive encephalopathy, cerebral hemorrhage/infarction, aortic dissection, acute MI, acute pulmonary edema, AKI, papilledema, retinal hemorrhage, eclampsia
- Management: Immediate ICU admission, intravenous antihypertensive agents (IV labetalol, IV nicardipine, IV sodium nitroprusside, IV clevidipine). Goal: reduce MAP by no more than 20-25% in the first hour (avoid abrupt large drops - cerebral autoregulation may be impaired). Gradual further reduction over 24-48 hours to 160/100 mmHg
- Brenner and Rector's The Kidney, 2-Volume Set; Morgan and Mikhail's Clinical Anesthesiology, 7e
Hypertensive Urgency
- Marked BP elevation (e.g., >200/130 mmHg) without target organ damage
- Management: Oral rapid-onset agents (captopril, clonidine), close outpatient monitoring, initiate/resume long-acting agents. Goal: reduce SBP/DBP to <160/100 mmHg over several hours
- Many of these patients have discontinued prior therapy - address adherence
- Brenner and Rector's The Kidney, 2-Volume Set
10. Special Populations
| Population | Key Consideration |
|---|---|
| Pregnancy | Avoid ACEi/ARBs (teratogenic). Use labetalol, methyldopa, nifedipine. Preeclampsia = HTN + proteinuria ≥20 weeks |
| CKD | ACEi/ARBs first-line for renoprotection; monitor K+ and creatinine. Avoid if bilateral renal artery stenosis |
| Elderly | Isolated systolic HTN common; start low, go slow; target <130 mmHg SBP if tolerated |
| Diabetes | ACEi/ARBs preferred; target <130/80 mmHg |
| Black patients | Higher prevalence, earlier onset, more severe end-organ damage; CCB + diuretic preferred; often need combination therapy from outset |
| Children/adolescents | Diagnose by normative data (≥95th percentile). Secondary causes more common than in adults |
11. Renal Artery Stenosis - Management Note
For atherosclerotic renal artery stenosis, medical therapy is generally preferred over revascularization. Three major RCTs (CORAL, ASTRAL, STAR) failed to prove superiority of percutaneous transluminal renal artery stenting (PTRAS) over optimal medical therapy. ACEi/ARBs are effective but must be used cautiously - they dilate efferent arterioles and may precipitate AKI in severe bilateral stenosis or stenosis of a solitary kidney. - Fuster and Hurst's The Heart, 15th Edition
12. Primary Aldosteronism - Adrenal Cortex Hypertension
- Aldosterone exerts ~90% of all mineralocorticoid activity in normal physiology
- In primary aldosteronism: autonomous aldosterone excess → Na+ retention, K+ secretion, volume expansion → hypertension + hypokalemia + metabolic alkalosis + suppressed renin
- Normally, the renal mineralocorticoid receptor (MR) is protected from cortisol by 11β-HSD2; licorice or ectopic ACTH inhibit this enzyme, causing apparent mineralocorticoid excess
- Low sodium diet attenuates both hypertension and hypokalemia in primary aldosteronism
- Fuster and Hurst's The Heart, 15th Edition
Sources
- Fuster and Hurst's The Heart, 15th Edition - Primary HTN pathophysiology, secondary causes, drug therapy, BP targets
- Harrison's Principles of Internal Medicine 22E (2025) - Classification, BP measurement
- Brenner and Rector's The Kidney, 2-Volume Set - Hypertensive crisis management
- Frameworks for Internal Medicine - Secondary HTN categories (vascular, endocrinologic, toxic)
- Textbook of Family Medicine 9e - HTN and PAD, risk factors
- Morgan and Mikhail's Clinical Anesthesiology, 7e - Hypertensive emergency definition
This is a shared conversation. Sign in to Orris to start your own chat.